Tandem Diabetes Care is exploding higher today following the announcement that the FDA has cleared the Tandem Mobi as the world's first and only tubeless automated insulin delivery system with up to seven days of wear. This significant regulatory milestone follows a separate announcement from the previous day regarding Health Canada's approval of a license amendment for the company's t:slim X2 insulin pump. Together, these international and domestic regulatory successes have served as the primary drivers for the stock's strong upward momentum.